Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ: APGE )

56.86 +2.37 (+4.35%)
Streaming Delayed Price Updated: 3:11 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Dow Dips Over 100 Points; Target Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.33% to 38,861.95 while the NASDAQ... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome
IPO stock Apogee eyed new highs Tuesday after its developmental inflammation treatment beat trial study objectives. 
Via Investor's Business Daily
Topics Initial Public Offering
Exposures Securities Market
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
From Apogee Therapeutics, LLC
Via GlobeNewswire
IPO watch 2024: Which new stocks will hit the market?
Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies. 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Apogee Therapeutics, LLC
Via GlobeNewswire
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. 
Via Benzinga
Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
From Apogee Therapeutics, LLC
Via GlobeNewswire
7 Biotech Stocks to Get In Now Before Investors Catch On
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. 
Via InvestorPlace
Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board
From Apogee Therapeutics, LLC
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics to Participate in Upcoming August Investor Conferences
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee, Sagimet Debut This Week In First Big IPOs Of Summer
Sagimet and Apogee both made their trading debuts this week, raising cash for their clinical trials after upsizing their respective IPOs. Inflammation and immunology biotech Apogee had the larger of... 
Via Talk Markets
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.